The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study (BRAD)

This study aims to test the hypothesis that insertion of an endorectal balloon into a patient receiving radical prostate radiotherapy by treatment radiographers is feasible without the patient experiencing undue discomfort. In addition this study will test the hypotheses that insertion of the rectal balloon prior to radiotherapy delivery stabilises rectal volume during radiotherapy treatment and minimises organ motion within the pelvis.

Study Overview

• Status: Unknown
• Conditions: Prostate Cancer
• Intervention / Treatment: Device: Endorectal Balloon insertion

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Manchester, United Kingdom, M20 4BX
    • Recruiting
    • Christie Hospital NHS Foundation Trust
    • Contact: Julie Stratford; Phone Number: 01614463506; Email: julie.stratford@christie.nhs.uk
    • Principal Investigator: Julie Stratford
    • Sub-Investigator: Ananya Choudhury

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Age greater than or equal to 18 years
• ECOG performance status 0-2 (Patients with PS-2 as a result of comorbidity will be excluded).
• Patients with histologically confirmed diagnosis of prostate adenocarcinoma
• Patients who are going to undergo treatment with radical radiotherapy for prostate cancer.
• Patients must be able to receive and understand verbal and written information regarding the study and give written, informed consent
• Patients must be able to comply with trial requirements.

Exclusion Criteria:

• Patients must not have a history of previous bowel surgery involving the rectum or anus.
• Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial, as well as any other serious uncontrolled medical condition.
• Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
• Pre-existing anorectal disease, e.g. Haemorrhoids, active bleeding, anal irritation, inflammatory bowel disease.
• Patients who are unable to give consent.
• Patients in clinical trials of new investigational medicinal products or treatment regimens unless there is written, prior agreement that the patient can also consent to this study, and that clinical data can also be used for this study.
• Prior pelvic radiotherapy

Study Plan

How is the study designed?

Design Details

• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Endorectal Balloon insertion; A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.	Device: Endorectal Balloon insertion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerability	The primary aim is to determine whether the balloon insertion is tolerated throughout treatment. The principle outcome measure is the percentage of patients who tolerate the endorectal balloon throughout treatment.	Patients will be assessed for 4 weeks throughout radiotherapy treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
rectal volume	Rectal volume stability will be determined by comparing the rectal volume for scans with the endorectal balloon(ERB)in situ to scans without the ERB in situ	patient scans will be reviewed over 4 weeks of radiotherapy
Assessment of planning target volume (PTV) coverage	PTV coverage and an assessment of prostate shape and position between the weekly imaging scans with the balloon in situ will be compared with the position of the prostate and PTV coverage on the original planning scan with the balloon in situ	patients will be reviewed across a 4 week radiotherapy treatment period.
Rectal wall sparing	Rectal wall sparing will be assessed by comparing the estimated dose determined from the imaging scans with the ERB in situ and not in situ against the planned dose from the radiotherapy planning scan	patients reviewed across 4 weeks of radiotherapy treatment
Acute toxicity	Acute toxicity according to CTCAE v. 4.0. This will record any reasons why balloon insertion is not possible for review.	patients toxicity will be assessed over 4 weeks of radiotherapy

Collaborators and Investigators

• Sponsor: The Christie NHS Foundation Trust
• Investigators: Principal Investigator: Julie Stratford, The Christie Nhs Foundation Trust

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Anticipated): December 1, 2014

Study Registration Dates

• First Submitted: April 17, 2013
• First Submitted That Met QC Criteria: April 25, 2013
• First Posted (Estimate): April 30, 2013

Study Record Updates

• Last Update Posted (Estimate): July 30, 2014
• Last Update Submitted That Met QC Criteria: July 29, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: 11_RADIO_101